Obstructive lung disease
diseaseOn this page
Summary
Obstructive lung disease (MONDO:0002267) is a disease and 31 clinical trials. Top therapeutic interventions include albuterol, olive oil, and vapendavir. A subtype of lung disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 31
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | obstructive lung disease |
| Mondo ID | MONDO:0002267 |
| MeSH | D008173 |
| DOID | DOID:2320 |
| UMLS | C0001883 |
| MedGen | 1387 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of lung disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › obstructive lung disease
Related subtypes (32): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary coin lesion, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, acute lung injury, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, respiratory failure, lung neoplasm, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease
Subtypes (1): chronic obstructive pulmonary disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
39 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Albuterol | Approved (phase 4) |
| Amlexanox | Approved (phase 4) |
| Beclomethasone Dipropionate | Approved (phase 4) |
| Benralizumab | Approved (phase 4) |
| Betamethasone | Approved (phase 4) |
| Bitolterol | Approved (phase 4) |
| Budesonide | Approved (phase 4) |
| Ciclesonide | Approved (phase 4) |
| Cromolyn | Approved (phase 4) |
| Dyphylline | Approved (phase 4) |
| Epinephrine | Approved (phase 4) |
| Fenoterol | Approved (phase 4) |
| Fenspiride | Approved (phase 4) |
| Flunisolide | Approved (phase 4) |
| Fluticasone Furoate | Approved (phase 4) |
| Fluticasone Propionate | Approved (phase 4) |
| Formoterol | Approved (phase 4) |
| Ibudilast | Approved (phase 4) |
| Indacaterol | Approved (phase 4) |
| Isoetharine | Approved (phase 4) |
| Isoproterenol | Approved (phase 4) |
| Mepolizumab | Approved (phase 4) |
| Metaproterenol | Approved (phase 4) |
| Mometasone Furoate | Approved (phase 4) |
| Montelukast | Approved (phase 4) |
| Nedocromil | Approved (phase 4) |
| Olodaterol | Approved (phase 4) |
| Omalizumab | Approved (phase 4) |
| Pirbuterol | Approved (phase 4) |
| Pranlukast | Approved (phase 4) |
| Reslizumab | Approved (phase 4) |
| Revefenacin | Approved (phase 4) |
| Roflumilast | Approved (phase 4) |
| Salmeterol | Approved (phase 4) |
| Seratrodast | Approved (phase 4) |
| Terbutaline | Approved (phase 4) |
| Tezepelumab | Approved (phase 4) |
| Triamcinolone | Approved (phase 4) |
| Zafirlukast | Approved (phase 4) |
| Bambuterol | Phase 3 (in late-stage trials) |
| Doxofylline | Phase 3 (in late-stage trials) |
| Procaterol | Phase 3 (in late-stage trials) |
| Theobromine | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone.
Clinical trials & evidence
Clinical trials
Clinical trials: 31.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 28 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02797275 | PHASE4 | ACTIVE_NOT_RECRUITING | Secondhand Smoke Respiratory Health Study |
| NCT00920127 | PHASE2/PHASE3 | UNKNOWN | Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study) |
| NCT06149494 | PHASE2 | COMPLETED | RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection |
| NCT02073708 | Not specified | ACTIVE_NOT_RECRUITING | A Population-based Investigation of Asthma in the Telemark Region of Norway |
| NCT03888300 | Not specified | RECRUITING | Measurement of Viscoelastic Properties of Bronchopulmonary Secretions. |
| NCT06563544 | Not specified | RECRUITING | FCV Vs VCV in Obstructive and Asthmatic Patients |
| NCT06963970 | Not specified | NOT_YET_RECRUITING | Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans |
| NCT01161680 | Not specified | COMPLETED | Breathing and Bones Initiative |
| NCT01337180 | Not specified | WITHDRAWN | Airway Inflammation Among Workers in the Silicon Carbide Processing Industry |
| NCT02185092 | Not specified | WITHDRAWN | Probiotic Use in Patients With Prior COPD Exacerbation |
| NCT02283008 | Not specified | UNKNOWN | Inhaler Technique Training |
| NCT02290535 | Not specified | COMPLETED | Electrical Impedance Tomography of Lung in Child and Young Age |
| NCT02506504 | Not specified | COMPLETED | Prevention of Post-exercise Muscle Fatigue and Effect on Exercise Training in Severe Patients With COPD. |
| NCT02820818 | Not specified | COMPLETED | Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood |
| NCT03087188 | Not specified | COMPLETED | Inhalation Therapy in Ambulant and Hospitalized Patient Using Available Film Sequences From the Internet |
| NCT03845257 | Not specified | TERMINATED | Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma |
| NCT04020081 | Not specified | UNKNOWN | A Study to Evaluate the Effect of Yoga Exercises and Meditation on Lung Function and Quality of Life in COPD Patients. |
| NCT04048408 | Not specified | COMPLETED | Comparison of Respiratory Muscle, Pain, Functional Performance and Cognitive Status in Obstructive Lung Diseases |
| NCT04050943 | Not specified | UNKNOWN | A Cohort of Patients With Chronic Pulmonary Disease |
| NCT04136951 | Not specified | COMPLETED | Improving Patient Prioritization During Hospital-homecare Transition |
| NCT04324684 | Not specified | COMPLETED | Prognostic Factors Keeping Track for COVID-19 Pneumonia |
| NCT04387799 | Not specified | COMPLETED | Determinants of COVID-19 Pneumonia (MC-19) |
| NCT04668599 | Not specified | COMPLETED | Cardio-pulmonary Rehabilitation and Sleep Quality |
| NCT04748900 | Not specified | COMPLETED | Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report |
| NCT04820556 | Not specified | COMPLETED | Gut Microbiota in Chronic Noncommunicable Diseases |
| NCT04919200 | Not specified | COMPLETED | Optimized Single-breath Helium Lung Volume in Obstructive Lung Disease |
| NCT05028985 | Not specified | UNKNOWN | Early COPD for China Pulmonary Health Study Stage II |
| NCT05250128 | Not specified | UNKNOWN | The Significance of Circulating Microvesicles in Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease |
| NCT05595733 | Not specified | COMPLETED | Can NAVA Mode Reduce Mechanical Ventilation Day in Patients With COPD ? |
| NCT05654597 | Not specified | TERMINATED | French Validation of the CAPTURE Case Finding Tool for Obstructive Respiratory Disease |
| NCT06801964 | Not specified | COMPLETED | AECOPD and Nutritional Supplementation in COPD |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALBUTEROL | 4 | 1 |
| OLIVE OIL | 4 | 1 |
| VAPENDAVIR | 2 | 1 |